Skip to main content
Erschienen in: Familial Cancer 3/2014

01.09.2014 | Original Article

Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history

verfasst von: Ava Kwong, Annie Tsz-Wai Chu, Christine Teen-Sum Wu, Desiree Man-Sik Tse

Erschienen in: Familial Cancer | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Western studies have shown that the uptake rates of surveillance and prophylaxis may vary among BRCA mutation carriers between ethnicities. The present study is the first to investigate the behavioural impact and subjective attitudes in Southern Chinese high-risk families who had undergone BRCA1 and BRCA2 genetic testing up to 2.5 years post-testing. Individuals who had such genetic testing and have consented to participate in the prospective database of Hong Kong Hereditary Breast Cancer Family Registry were recruited and surveyed by a face-to-face or telephone interview. Sociodemographic information, genetic test results, pre- and post-testing surveillance, medical regimes, and attitudes towards the choice of clinical management were obtained by interviews and retrieval of medical records using this prospective database. 69 females with breast cancer history were recruited into the study. Twenty-nine female carriers (15 BRCA1 mutated gene-carriers and 14 BRCA2 mutated gene-carriers) and 40 non-carriers of a BRCA 1/2 mutations were interviewed. The uptake rate of high risk breast screening i.e. clinical breast examination, mammography, and breast MRI is significantly higher among female carriers (48.3 %) after knowing genetic testing results than before (p < 0.01). A strong significant relationship between any increase or decrease of ovarian ultrasound screening (OS) and genetic status is found (p < .001), with more females did OS and with a higher frequency after knowing genetic testing results among both carriers (22.7 % → 86.4 %) and non-carriers (37.5 % → 50.0 %). Among carriers, very few opted for prophylactic surgeries. The present cohort might see prophylaxis as last resort and would use traditional Chinese medicine in cancer risk management.
Literatur
1.
Zurück zum Zitat Wevers M, Ausems M, Verhoef S, Bleiker E, Hahn D, Hogervorst F, van der Luijt R, Valdimarsdottir H, van Hillegersberg R, Rutgers E, Aaronson N (2011) Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer 11:6PubMedPubMedCentralCrossRef Wevers M, Ausems M, Verhoef S, Bleiker E, Hahn D, Hogervorst F, van der Luijt R, Valdimarsdottir H, van Hillegersberg R, Rutgers E, Aaronson N (2011) Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer 11:6PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg Å, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedPubMedCentralCrossRef Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg Å, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedPubMedCentralCrossRef Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat King M-C, Marks JH, Mandell JB, Group TNYBCS (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRef King M-C, Marks JH, Mandell JB, Group TNYBCS (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRef
5.
Zurück zum Zitat Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324PubMedCrossRef Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324PubMedCrossRef
6.
Zurück zum Zitat Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordière A, Vincent-Salomon A, Salmon R, Campana F, Kirova YM, Dendale R, Fourquet A (2007) Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 82:272–280PubMedCrossRef Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordière A, Vincent-Salomon A, Salmon R, Campana F, Kirova YM, Dendale R, Fourquet A (2007) Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 82:272–280PubMedCrossRef
7.
Zurück zum Zitat Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227–238PubMedCrossRef Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227–238PubMedCrossRef
8.
Zurück zum Zitat Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP (1999) Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 17:1040–1046PubMed Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP (1999) Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 17:1040–1046PubMed
9.
Zurück zum Zitat Parmigiani G, Berry DA, Aguilar O (1998) Determining carrier probabilities for breast cancer–susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158PubMedPubMedCentralCrossRef Parmigiani G, Berry DA, Aguilar O (1998) Determining carrier probabilities for breast cancer–susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Parmigiani G, Berry DA, Iversen JE, Joellen S, Winer EP (1999) Modeling risk of breast cancer and decisions about genetic testing. In: Gatsonis C, Carlin B, Gelman A, West M, Kass RE, Carriquiry A, Verdinelli I (eds) Case studies in bayesian statistics iv. Springer, New York, pp 173–268 Parmigiani G, Berry DA, Iversen JE, Joellen S, Winer EP (1999) Modeling risk of breast cancer and decisions about genetic testing. In: Gatsonis C, Carlin B, Gelman A, West M, Kass RE, Carriquiry A, Verdinelli I (eds) Case studies in bayesian statistics iv. Springer, New York, pp 173–268
11.
Zurück zum Zitat Gomez SL, Clarke CA, Shema SJ, Chang ET, Keegan TH, Glaser SL (2010) Disparities in breast cancer survival among Asian women by ethnicity and immigrant status: a population-based study. Am J Public Health 100:861–869PubMedPubMedCentralCrossRef Gomez SL, Clarke CA, Shema SJ, Chang ET, Keegan TH, Glaser SL (2010) Disparities in breast cancer survival among Asian women by ethnicity and immigrant status: a population-based study. Am J Public Health 100:861–869PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Pham J, Allen L, Gomez S (2009) Why do Asian-American women have lower rates of breast conserving surgery: results of a survey regarding physician perceptions. BMC Public Health 9:246PubMedPubMedCentralCrossRef Pham J, Allen L, Gomez S (2009) Why do Asian-American women have lower rates of breast conserving surgery: results of a survey regarding physician perceptions. BMC Public Health 9:246PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. Ii. BRCA1 and BRCA2. Cancer genetics studies consortium. JAMA 277:997–1003 Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. Ii. BRCA1 and BRCA2. Cancer genetics studies consortium. JAMA 277:997–1003
14.
Zurück zum Zitat Kriege M, Brekelmans CTM, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MMA, Muller SH, Meijer S, Oosterwijk JC, Beex LVAM, Tollenaar RAEM, de Koning HJ, Rutgers EJT, Klijn JGM (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437PubMedCrossRef Kriege M, Brekelmans CTM, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MMA, Muller SH, Meijer S, Oosterwijk JC, Beex LVAM, Tollenaar RAEM, de Koning HJ, Rutgers EJT, Klijn JGM (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437PubMedCrossRef
15.
Zurück zum Zitat Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM, Group MS (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (maribs). Lancet 365:1769–1778PubMedCrossRef Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM, Group MS (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (maribs). Lancet 365:1769–1778PubMedCrossRef
16.
Zurück zum Zitat Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325PubMedCrossRef Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325PubMedCrossRef
17.
Zurück zum Zitat National institutes of health consensus development conference statement (1994) Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 55:S4–14CrossRef National institutes of health consensus development conference statement (1994) Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 55:S4–14CrossRef
18.
Zurück zum Zitat Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, Schiefloe A, Hagen B, Himmelmann A, Jerve F, Shetelig K, Fjaerestad I, Tropé C, Møller P (1999) Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 78:906–911PubMedCrossRef Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, Schiefloe A, Hagen B, Himmelmann A, Jerve F, Shetelig K, Fjaerestad I, Tropé C, Møller P (1999) Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 78:906–911PubMedCrossRef
19.
Zurück zum Zitat Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773–1779PubMedCrossRef Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773–1779PubMedCrossRef
21.
Zurück zum Zitat Brown S, McLaughlin M, Pope K, Haile K, Hughes L, Israel PZ (2009) Initial radiation experience evaluating early tolerance and toxicities in patients undergoing accelerated partial breast irradiation using the contura multi-lumen balloon breast brachytherapy catheter. Brachytherapy 8:227–233PubMedCrossRef Brown S, McLaughlin M, Pope K, Haile K, Hughes L, Israel PZ (2009) Initial radiation experience evaluating early tolerance and toxicities in patients undergoing accelerated partial breast irradiation using the contura multi-lumen balloon breast brachytherapy catheter. Brachytherapy 8:227–233PubMedCrossRef
22.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst 97:1652–1662PubMedCrossRef Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst 97:1652–1662PubMedCrossRef
23.
Zurück zum Zitat Nusbaum R, Peshkin BN, DeMarco TA, Goodenberger M (2009) BRCA1/2 testing in patients with newly diagnosed breast cancer. Community Oncol 6:367–371CrossRef Nusbaum R, Peshkin BN, DeMarco TA, Goodenberger M (2009) BRCA1/2 testing in patients with newly diagnosed breast cancer. Community Oncol 6:367–371CrossRef
24.
Zurück zum Zitat Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121:225–231PubMedCrossRef Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121:225–231PubMedCrossRef
25.
Zurück zum Zitat Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ‘t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the prose study group. J Clin Oncol 22:1055–1062PubMedCrossRef Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ‘t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the prose study group. J Clin Oncol 22:1055–1062PubMedCrossRef
26.
Zurück zum Zitat Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164PubMedCrossRef Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164PubMedCrossRef
27.
Zurück zum Zitat Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef
28.
Zurück zum Zitat Society of Gynecologic Oncologists Clinical Practice Committee (2005) Society of gynecologic oncologists clinical practice committee statement on prophylactic salpingo-oophorectomy. Gynecol Oncol 98:179–181 Society of Gynecologic Oncologists Clinical Practice Committee (2005) Society of gynecologic oncologists clinical practice committee statement on prophylactic salpingo-oophorectomy. Gynecol Oncol 98:179–181
29.
Zurück zum Zitat Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11:1030–1034PubMedCrossRef Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11:1030–1034PubMedCrossRef
30.
Zurück zum Zitat Boughey JC, Hoskin TL, Degnim AC, Sellers TA, Johnson JL, Kasner MJ, Hartmann LC, Frost MH (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17:2702–2709PubMedPubMedCentralCrossRef Boughey JC, Hoskin TL, Degnim AC, Sellers TA, Johnson JL, Kasner MJ, Hartmann LC, Frost MH (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17:2702–2709PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F (2004) Contralateral prophylactic mastectomy: predictors of significant histologic findings. Cancer 101:1977–1986PubMedCrossRef Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F (2004) Contralateral prophylactic mastectomy: predictors of significant histologic findings. Cancer 101:1977–1986PubMedCrossRef
32.
Zurück zum Zitat Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23:4275–4286PubMedCrossRef Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23:4275–4286PubMedCrossRef
33.
Zurück zum Zitat McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938–3943PubMed McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938–3943PubMed
34.
Zurück zum Zitat van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van’t Veer LJ, Tollenaar RA (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93:287–292PubMedPubMedCentralCrossRef van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van’t Veer LJ, Tollenaar RA (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93:287–292PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180:439–445PubMedCrossRef Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180:439–445PubMedCrossRef
36.
Zurück zum Zitat Bennett P, Wilkinson C, Turner J, Griffith G, France B, Brain K, Gray J (2007) The impact of breast cancer genetic risk assessment on intentions to perform cancer surveillance behaviors. J Genet Couns 16:617–623PubMedCrossRef Bennett P, Wilkinson C, Turner J, Griffith G, France B, Brain K, Gray J (2007) The impact of breast cancer genetic risk assessment on intentions to perform cancer surveillance behaviors. J Genet Couns 16:617–623PubMedCrossRef
37.
Zurück zum Zitat Lerman C, Hughes C, Croyle RT, Main D, Durham C, Snyder C, Bonney A, Lynch JF, Narod SA, Lynch HT (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31:75–80PubMedCrossRef Lerman C, Hughes C, Croyle RT, Main D, Durham C, Snyder C, Bonney A, Lynch JF, Narod SA, Lynch HT (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31:75–80PubMedCrossRef
38.
Zurück zum Zitat Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, Chan A, Hamann HA, Lerman C, McDonald J, Venne V, Ward JH, Lyon E (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118A:201–209PubMedCrossRef Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, Chan A, Hamann HA, Lerman C, McDonald J, Venne V, Ward JH, Lyon E (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118A:201–209PubMedCrossRef
39.
Zurück zum Zitat Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG (2003) Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21:1675–1681PubMedCrossRef Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG (2003) Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21:1675–1681PubMedCrossRef
40.
Zurück zum Zitat Morris KT, Johnson N, Krasikov N, Allen M, Dorsey P (2001) Genetic counseling impacts decision for prophylactic surgery for patients perceived to be at high risk for breast cancer. Am J Surg 181:431–433PubMedCrossRef Morris KT, Johnson N, Krasikov N, Allen M, Dorsey P (2001) Genetic counseling impacts decision for prophylactic surgery for patients perceived to be at high risk for breast cancer. Am J Surg 181:431–433PubMedCrossRef
41.
Zurück zum Zitat Watson M, Kash KM, Homewood J, Ebbs S, Murday V, Eeles R (2005) Does genetic counseling have any impact on management of breast cancer risk? Genet Test 9:167–174PubMedCrossRef Watson M, Kash KM, Homewood J, Ebbs S, Murday V, Eeles R (2005) Does genetic counseling have any impact on management of breast cancer risk? Genet Test 9:167–174PubMedCrossRef
42.
Zurück zum Zitat Kwong A, Cheung P, Chan S, Lau S (2008) Breast cancer in Chinese women younger than age 40: are they different from their older counterparts? World J Surg 32:2554–2561PubMedCrossRef Kwong A, Cheung P, Chan S, Lau S (2008) Breast cancer in Chinese women younger than age 40: are they different from their older counterparts? World J Surg 32:2554–2561PubMedCrossRef
43.
Zurück zum Zitat Kwong A, Wong L, Chan K, Ma E, Khoo U, Ford J (2008) Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Fam Cancer 7:125–133PubMedCrossRef Kwong A, Wong L, Chan K, Ma E, Khoo U, Ford J (2008) Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Fam Cancer 7:125–133PubMedCrossRef
44.
Zurück zum Zitat Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Suen DT, Choi C, Ho LS, Kwan KH, Poon M, Wong TT, Chan K, Chan SW, Ying MW, Chan WC, Ma ES, Ford JM, West DW (2009) Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hugo J 3:63–76PubMedPubMedCentralCrossRef Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Suen DT, Choi C, Ho LS, Kwan KH, Poon M, Wong TT, Chan K, Chan SW, Ying MW, Chan WC, Ma ES, Ford JM, West DW (2009) Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hugo J 3:63–76PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Julian-Reynier CM, Bouchard LJ, Evans DG, Eisinger FA, Foulkes WD, Kerr B, Blancquaert IR, Moatti JP, Sobol HH (2001) Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92:959–968PubMedCrossRef Julian-Reynier CM, Bouchard LJ, Evans DG, Eisinger FA, Foulkes WD, Kerr B, Blancquaert IR, Moatti JP, Sobol HH (2001) Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92:959–968PubMedCrossRef
46.
Zurück zum Zitat Ku C-F, Koo M (2012) Association of distress symptoms and use of complementary medicine among patients with cancer. J Clin Nurs 21:736–744PubMedCrossRef Ku C-F, Koo M (2012) Association of distress symptoms and use of complementary medicine among patients with cancer. J Clin Nurs 21:736–744PubMedCrossRef
47.
Zurück zum Zitat Zhi C, Kai G, Ying Z, Wei Z, Wei L, Xiao OuS (2008) The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med 14:1049–1055CrossRef Zhi C, Kai G, Ying Z, Wei Z, Wei L, Xiao OuS (2008) The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med 14:1049–1055CrossRef
48.
Zurück zum Zitat Alamian A, Rouleau I, Simard J, Dorval M (2006) Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility. Nutr Cancer 54:157–165PubMedCrossRef Alamian A, Rouleau I, Simard J, Dorval M (2006) Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility. Nutr Cancer 54:157–165PubMedCrossRef
49.
Zurück zum Zitat Rakovitch E, Pignol J-P, Chartier C, Ezer M, Verma S, Dranitsaris G, Clemons M (2005) Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat 90:139–148PubMedCrossRef Rakovitch E, Pignol J-P, Chartier C, Ezer M, Verma S, Dranitsaris G, Clemons M (2005) Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat 90:139–148PubMedCrossRef
50.
Zurück zum Zitat Kwong A, Wong CH, Shea C, Suen DT, Choi CL (2010) Choice of management of southern Chinese BRCA mutation carriers. World J Surg 34:1416–1426PubMedCrossRef Kwong A, Wong CH, Shea C, Suen DT, Choi CL (2010) Choice of management of southern Chinese BRCA mutation carriers. World J Surg 34:1416–1426PubMedCrossRef
Metadaten
Titel
Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history
verfasst von
Ava Kwong
Annie Tsz-Wai Chu
Christine Teen-Sum Wu
Desiree Man-Sik Tse
Publikationsdatum
01.09.2014
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 3/2014
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9706-7

Weitere Artikel der Ausgabe 3/2014

Familial Cancer 3/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.